2018
DOI: 10.1021/acs.joc.8b02751
|View full text |Cite
|
Sign up to set email alerts
|

Convergent Synthesis of PI3K Inhibitor GDC-0908 Featuring Palladium-Catalyzed Direct C–H Arylation toward Dihydrobenzothienooxepines

Abstract: A practical convergent synthesis of PI3K inhibitor GDC-0908 (1) is described. The process features a dihydrobenzothienooxepine formation via palladium-catalyzed intramolecular direct C–H arylation and a Negishi coupling to construct the key C–C bonds. We further developed a general synthesis of dihydrobenzothienooxepines in good to excellent yields via palladium-catalyzed intramolecular direct C–H arylation, which tolerates both electronically and sterically diverse substituents on the phenyl ring.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
1
0
2

Year Published

2020
2020
2023
2023

Publication Types

Select...
3
1
1

Relationship

0
5

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 25 publications
0
1
0
2
Order By: Relevance
“…In 2018, Zhang et al developed a convergent synthetic route for the synthesis of GDC-0908 ( 74), a therapeutic development agent for cancer treatment (Scheme 18). [67] The most recent studies, from 2021, show that the API is in Phase I/II for the treatment of solid cancers. [68] The discovery route of 74 had an overall yield of 1 %.…”
Section: Palladiummentioning
confidence: 99%
“…In 2018, Zhang et al developed a convergent synthetic route for the synthesis of GDC-0908 ( 74), a therapeutic development agent for cancer treatment (Scheme 18). [67] The most recent studies, from 2021, show that the API is in Phase I/II for the treatment of solid cancers. [68] The discovery route of 74 had an overall yield of 1 %.…”
Section: Palladiummentioning
confidence: 99%
“…einen konvergenten Syntheseweg für die Synthese von GDC‐0908 ( 74 ), einem therapeutischen Wirkstoff für die Krebsbehandlung (Schema 18). [67] …”
Section: C−h‐aktivierung Im Präparativen Maßstab In Der Medizinischen...unclassified
“…Im Jahr 2011 berichteten Cook et al über die Synthese von 3-PCB und βCCt über eine intramolekulare Pd-katalysierte CÀ H-Arylierung (Schema 16A), [63] 74), einem therapeutischen Wirkstoff für die Krebsbehandlung (Schema 18). [67] Die jüngsten Studien aus dem Jahr 2021 zeigen, dass sich der Wirkstoff in Phase I/II für die Behandlung von soliden Krebserkrankungen befindet. [68] LY2784522 (78) ist ein Wirkstoff, der sich in Phase-II-Studien für die Behandlung verschiedener myeloproliferativer Erkrankungen befindet.…”
Section: Palladiumunclassified